by asormani
Posted on: October 8, 2012 by asormaniNo Comments »
arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.
by cnolan
Posted on: December 1, 2011 by cnolanNo Comments »
arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.
Yahoo’s $1.1 billion planned purchase of blogging site Tumblr is the largest exit of a pre-public venture-backed New York-based company
Author : mboslet
It’s that time of the year when every VC (or, well, most VCs) secretly pulls up Forbes’ Midas list and,
Author : mahendra
Venture-backed IPO activity has been sluggish so far this year, but there are signs this could change. Two recent issues,
Author : mboslet
The Michigan Venture Capital Association said 29 venture capital firms now do business in the state and contributed to the
Author : mboslet
MassChallenge said it selected 128 startups for its 2013 MassChallenge Accelerator Program. The companies come from eighteen states and 11
Author : mboslet
Welcome! Join the peHUB community to make connections, share your opinion, and follow your favorite authors. It's quick and easy.
Click here to get started!
reuters-news wrote a new post, Valeant Near Deal to Acquire Bausch & Lomb: Source 13 hours ago
